Debanjana Chatterjee has given his Buy rating due to a combination of factors that highlight both Intellia’s clinical progress and its risk-management strategy. He views the Phase 3 MAGNITUDE trial for nex-z as having a more favorable setup than eplontersen’s CARDIO-TTRansform, given its event-driven design and the deeper, more durable TTR reduction observed with nex-z, which could support differentiated cardiovascular outcomes despite similar background stabilizer use.

At the same time, he sees the emerging link between HLA-C*05:01 genotype and liver enzyme elevations as a path to refine patient selection and improve the overall benefit-risk profile. He also emphasizes the strong hereditary angioedema franchise, with lonvo-z showing robust reductions in attack rates and progressing toward a U.S. launch in 2027, all of which underpins his unchanged $29 price target and supports the Buy recommendation.